Jun 2026 (Q2 FY26) — Jul 30, 2026
AXT Q2 FY26 — Record Revenue and Indium Phosphide Growth
Read the full callAXT (AXTI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AXT earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 47.6 | +164.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 21.9 | +59.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 11.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$56.79 +10.34% · +$5.32
Performance +1159.2% 1Y
1Y: $4.51 on 17 Oct 2025 → $56.79. High $140.83 (22 May 2026), low $4.51 (17 Oct 2025).
- Previous close
- $51.47
- 52-week range
- $4.91 – $140.83
- One year
- +1056.62%
Overview
- Symbol
- AXTI
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AXT earnings calls (AXTI)
Financials
What the filings say
Net profit, year on year: +259% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 25 | 19 | 18 | 28 | 23 | 27 | 48 |
| Operating profit | -3 | -6 | -10 | -7 | -1 | -4 | -2 | 10 |
| Operating margin | −14.4% | −24.6% | −53.1% | −37.5% | −4.0% | −16.6% | −5.9% | 21.9% |
| Interest | 0 | 0 | — | 0 | 0 | 0 | — | — |
| Profit before tax | -2 | -6 | -10 | -7 | -1 | -3 | -1 | 15 |
| Tax rate | −27.7% | −2.0% | −0.7% | −8.2% | −43.1% | −15.0% | −40.8% | 13.9% |
| Net profit | -3 | -5 | -9 | -7 | -2 | -4 | -2 | 11 |
| EPS ($ per share) | -0.07 | — | -0.20 | -0.16 | -0.04 | — | -0.03 | 0.18 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -45 | -48 | -45 | -30 | -14 | -32 | -44 | -65 |
| Total liabilities | 29 | 31 | 43 | 52 | 80 | 90 | 84 | 99 |
| Fixed assets | 82 | 97 | 116 | 142 | 161 | 166 | 160 | 162 |
| Investments | 22 | 9 | 0 | 5 | 9 | 2 | — | 0 |
| Total assets | 224 | 223 | 299 | 332 | 370 | 359 | 339 | 434 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | 13 | 6 | -3 | -9 | 3 | -12 | -13 |
| Cash from investing | -31 | -8 | -16 | -39 | -25 | -3 | -4 | -7 |
| Cash from financing | 0 | 6 | 53 | 6 | 38 | 9 | -1 | 107 |
| Net cash flow | -28 | 10 | 46 | -36 | 5 | 9 | -16 | 95 |
| Capital expenditure | -41 | -22 | -20 | -30 | -28 | -10 | -6 | -6 |
| Free cash flow | -37 | -9 | -14 | -33 | -37 | -7 | -18 | -19 |
AXTI revenue by segment
Substrates grew from 71% to 79% of revenue over the last two years.
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Substrates | 71% | 63% | 57% | 63% | 76% | 66% | 72% | 79% | +232.7% |
| Raw Materials and Other | — | — | — | 37% | 24% | — | 28% | 21% | +50.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- CN 65% ↑ 6 pt
- Europe 19% ↑ 8 pt
- Asia Pacific Excluding China Taiwan and Japan 7%
- TW 5% ↓ 4 pt
- JP 3% ↓ 4 pt
- North America <1% ↓ 10 pt
As AXTI cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
78 filings between Oct 20, 2025 and Aug 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$78.77M
50 sales by 5 insiders
Compensation
not trading decisions- 7
- Award — granted as compensation
- 11
- Option exercise — converted options into shares
Also filed: 10 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| YOUNG MORRIS S | — | $39.41M | Jun 2, 2026 |
| FISCHER GARY L | — | $23.24M | Mar 13, 2026 |
| CHEN JESSE | — | $10.25M | Jun 15, 2026 |
| CHANG DAVID C | — | $5.23M | Jun 15, 2026 |
| LEBLANC LEONARD J | — | $636.3K | Aug 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | LEBLANC LEONARD J Director | Sale | 4,000 | $384.3K |
| Aug 7, 2026 | LEBLANC LEONARD J Director | Sale | 2,000 | $176.6K |
| Jun 15, 2026 | CHANG DAVID C Director | Sale | 8,333 | $926.4K |
| Jun 15, 2026 | CHEN JESSE Director | Sale | 6,172 | $711.3K |
| Jun 12, 2026 | YOUNG MORRIS S CEO | Gift | 1,200 | $0 |
| Jun 12, 2026 | CHEN JESSE Director | Sale | 13,000 | $1.25M |
| Jun 11, 2026 | CHEN JESSE Director | Sale | 9,000 | $796.9K |
| Jun 10, 2026 | LEBLANC LEONARD J Director | Sale | 500 | $44.8K |
| Jun 10, 2026 | CHEN JESSE Director | Sale | 9,000 | $780.6K |
| Jun 9, 2026 | CHEN JESSE Director | Sale | 1,500 | $139.9K |
| Jun 8, 2026 | CHEN JESSE Director | Sale | 6,000 | $564.0K |
| Jun 4, 2026 | CHANG DAVID C Director | Award | 754 | — |
| Jun 4, 2026 | LEBLANC LEONARD J Director | Award | 754 | — |
| Jun 4, 2026 | CHEN JESSE Director | Sale | 6,133 | $664.1K |
| Jun 4, 2026 | CHEN JESSE Director | Award | 754 | — |
| Jun 3, 2026 | CHEN JESSE Director | Sale | 4,000 | $445.4K |
| Jun 2, 2026 | YOUNG MORRIS S CEO | Option exercise | 11,806 | $61.5K |
| Jun 2, 2026 | YOUNG MORRIS S CEO | Sale | 123,601 | $14.01M |
| Jun 2, 2026 | CHEN JESSE Director | Sale | 2,000 | $222.1K |
| Jun 1, 2026 | CHEN JESSE Director | Sale | 3,200 | $357.0K |
| Jun 1, 2026 | YOUNG MORRIS S CEO | Option exercise | 73,897 | $385.0K |
| Jun 1, 2026 | YOUNG MORRIS S CEO | Sale | 73,897 | $8.31M |
| May 1, 2026 | YOUNG MORRIS S CEO | Gift | 6,500 | $0 |
| May 1, 2026 | YOUNG MORRIS S CEO | Gift | 7,500 | $0 |
| Mar 13, 2026 | YOUNG MORRIS S CEO | Sale | 37,905 | $1.94M |
| Mar 13, 2026 | FISCHER GARY L CFO | Sale | 80,776 | $4.09M |
| Mar 13, 2026 | CHEN JESSE Director | Sale | 8,083 | $406.2K |
| Mar 12, 2026 | CHEN JESSE Director | Sale | 6,003 | $293.9K |
| Mar 12, 2026 | FISCHER GARY L CFO | Sale | 8,256 | $414.4K |
| Mar 11, 2026 | CHEN JESSE Director | Sale | 15,000 | $706.9K |
| Mar 10, 2026 | YOUNG MORRIS S CEO | Sale | 30,832 | $1.41M |
| Mar 10, 2026 | CHEN JESSE Director | Sale | 14,000 | $646.1K |
| Mar 10, 2026 | CHANG DAVID C Director | Sale | 20,000 | $919.9K |
| Mar 9, 2026 | CHEN JESSE Director | Sale | 12,452 | $469.3K |
| Mar 9, 2026 | YOUNG MORRIS S CEO | Sale | 125,893 | $4.60M |
| Mar 6, 2026 | YOUNG MORRIS S CEO | Sale | 8,300 | $329.1K |
| Mar 6, 2026 | CHEN JESSE Director | Sale | 2,000 | $73.3K |
| Mar 5, 2026 | CHEN JESSE Director | Sale | 11,147 | $426.5K |
| Mar 5, 2026 | CHANG DAVID C Director | Sale | 20,000 | $768.5K |
| Mar 4, 2026 | CHEN JESSE Director | Sale | 8,800 | $341.7K |
| Mar 4, 2026 | CHANG DAVID C Director | Sale | 20,000 | $770.6K |
| Mar 3, 2026 | YOUNG MORRIS S CEO | Gift | 3,780 | $0 |
| Mar 3, 2026 | CHEN JESSE Director | Sale | 11,007 | $445.7K |
| Mar 2, 2026 | YOUNG MORRIS S CEO | Gift | 10,000 | $0 |
| Mar 2, 2026 | FISCHER GARY L CFO | Sale | 405,233 | $16.80M |
| Mar 2, 2026 | YOUNG MORRIS S CEO | Gift | 17,200 | $0 |
| Mar 2, 2026 | YOUNG MORRIS S CEO | Sale | 159,536 | $6.91M |
| Mar 2, 2026 | CHEN JESSE Director | Sale | 11,320 | $516.1K |
| Feb 26, 2026 | FISCHER GARY L CFO | Option exercise | 34,203 | $324.9K |
| Feb 26, 2026 | FISCHER GARY L CFO | Option exercise | 65,685 | $342.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AXT INC
Free account. Everything above stays public.
Write why you follow AXT INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading